Targeted therapeutics hold tremendous promise in inhibiting cancer cell proliferation. However, targeting proteins individually can be compensated for by bypass mechanisms and activation of regulatory loops. Designing optimal therapeutic combinations must therefore take into consideration the complex dynamic networks in the cell. In this study, we analyzed the insulinlike growth factor (IGF-1) signaling network in the MDA-MB231 breast cancer cell line. We used reverse phase protein array to measure the transient changes in the phosphorylation of proteins after IGF-1 stimulation. We developed a computational procedure that integrated massaction modeling with particle swarm optimization to train the model against the experimental data and infer the unknown model parameters. The trained model was used to predict how targeting individual signaling proteins altered the rest of the network and identify drug combinations that minimally increased phosphorylation of other proteins elsewhere in the network. Experimental testing of the modeling predictions showed that optimal drug combinations inhibited cell signaling and proliferation, while non-optimal combination of inhibitors increased phosphorylation of non-targeted proteins and rescued cells from cell death.
Introduction
Cell signaling networks are complex systems that integrate information from the cellular environment (1) (2) (3) (4) (5) . Maps of complex networks were derived by interconnecting the individual pathways obtained from experimental data (6, 7) . These studies revealed that signaling networks contain numerous features, such as feedback and feedforward loops (8, 9) , which render virtually impossible for the human mind to decipher how signals are integrated within the pathways. Thus, computational approaches are needed to elucidate the regulatory properties of signaling networks (10) (11) (12) .
Several groups have used ordinary differential equations (ODEs) to analyze the dynamics of signaling networks and generate experimentally testable predictions (6, (13) (14) (15) (16) (17) . The use of mass-action ODE modeling, however, is impaired because of incomplete knowledge about the concentrations and kinetics of signaling intermediates.
Inferring the parameters for mass-action modeling in signaling networks is challenging.
The most common approach is to obtain parameters from the literature and fit the models to the experimental data to infer those that remain unknown (6, 13, (18) (19) (20) (21) (22) (23) (24) . Unfortunately, the kinetic parameters reported in the literature may differ by orders of magnitude, depending on experimental conditions. Thus, it is difficult to determine whether discrepancies between computational and experimental data are due to inaccurate measures or incomplete modeling.
Parameter estimation can be effectively accomplished using optimization methods, which enable quantitative model fitting to experimental data (25-31). However, the experimental techniques used to measure the activity of signaling proteins mainly provide qualitative or semi-quantitative data. Optimization strategies are thus needed to identify sets of model parameters that equally fit the qualitative experimental data. , and K 2 are the forward, reverse, and dissociation kinetic rate constants, respectively.
Step 2: The set of chemical reactions was transformed into a system of coupled ODEs by assuming that the dynamics of IGFR network obeyed the law of mass-action. Specifically, the accumulation rate of the concentration of the ith signaling intermediate was expressed as the difference between its net rates of production (r p,i ) and consumption (r c,i ). Thus, the accumulation rate of the concentration of MEK* was expressed as follows: The list of chemical reactions that described the consensus activation and inhibition mechanisms of proteins involved in the IGFR network and the corresponding system of ODEs are listed in Supplemental Material S1. To implement mass-action modeling, it was necessary to infer the unknown model parameters, which are the kinetic rate constants and the initial concentrations of the proteins. In this regard, we trained the mass-action model against transient data measured by RPPA using particle swarm optimization (PSO). We selected PSO because of its superior ability to converge to more optimal solutions compared to other optimization algorithms (see discussion).
PSO. PSO is a stochastic algorithm that mimicks the behavior of swarms of animals that search for food (36) . Particles in the swarm have a position x ij , a velocity v ij , and a fitness f i , where i and j represent the number of particles and the dimension of the space solution, respectively. Each (
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In equations 3, ω is the inertia factor, r 1 and r 2 are two random numbers uniformly distributed in the interval [0,1], and c 1 and c 2 are the coefficients of self-recognition and social component (see (37) and Supplemental Material S2 for details on parameters in Equations 3).
In our settings, the particle positions represented the unknown parameter values used in the mass-action model to generate computationally the time courses of proteins that are measured by RPPA, the particle velocities denoted the extent to which the parameter values were iteratively changed, and the particle fitness was defined as the distance between the time courses of proteins experimentally and computationally measured. Model parameters were randomly initialized and iteratively changed according to equations 3 until the distance between the time courses of the measured and predicted proteins was minimal (i.e. optimal fitness). The distance between computed and measured time courses was evaluated using the standard deviation (SD)-weighted square error: Technology, Boston, MA); anti-GSK3 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).
Immunoblotting. Immunoblotting was performed using standard procedures.
RPPA. Serial diluted lysates were arrayed on nitrocellulose-coated FAST slides (Whatman, Kent, UK) using the Aushon 2470 Arrayer (Aushon Biosystems, Billerica, MA). Each slide was probed with a primary antibody plus a biotin-conjugated secondary antibody. The signal was amplified using the DakoCytomation-catalyzed system (Dako, Carpinteria, CA) and visualized using a "readout" molecules to fit ODE models to experimental data and infer unknown parameters (14, 15, 26) . In our study, we trained our model using six "readout" proteins and 126 experimental data points combined into a scalar fitness.
Because of the substantial degree of uncertainty in parameter estimation, fitting massaction models to the qualitative data measured on RPPA required the identification of multiple trajectories that equally resembled the measured protein profiles. Using the integrative massaction modeling-PSO procedure, we identified 10 sets of model parameters that equally fit the measured data (Supplemental File S1). We characterized the parameter regimens by ranking the parameters according to their coefficient of variation (CV) and found that 69% of them had a CV smaller than 1 ( Figure 1C) . We calculated the means and SD of the identified trajectories to represent the entire set and the fitting variability. Figure 1B shows the mean trajectories and the fitting variability identified by the mass-action model, which had been trained using PSO against normalized protein profiles measured on RPPA after IGF-1 stimulation of MDA-MB231 cells.
The simulation results indicated that the integrative procedure adequately fit the time courses of all measured proteins.
Model testing. To determine the ability of the trained model to correctly generate responses to perturbations that have not been explicitly included in the training data set, we used it to predict the dynamics of the IGFR network after inhibition of MEK. Figure 2A The computational results were experimentally tested using an independent set of 252 data points measured by RPPA. Figure 2B shows the levels of p-AKT, p-MAPK, p-GSK3, pmTOR, p-p70S6K, and p-TSC2 detected in triplicate in IGF-1-stimulated MDA-MB231 cells in the absence of the MEK inhibitor and after 4 hours of incubation with the MEK inhibitor. The experimental data indicated that MEK inhibition increased p-AKT and p-TSC2 levels, decreased p-MAPK and p-p70S6K levels, and slightly decreased p-GSK3 levels but had no significant effect on p-mTOR levels. Despite the limited discrepancy between the computed and measured profiles of p-GSK3, the experimental results adequately matched those predicted by the model. Therefore, the trained mass-action model correctly predicted the effect of MEK inhibition on IGFR dynamics.
Predicting inhibition of targeted molecules
Individual inhibition of targeted molecules. To determine how to select drugs with the ability to inhibit the pathways measured in MDA-MB231 cells, we used the trained and tested mass-action model to predict the response of IGFR network after molecules in the network had been individually inhibited (Supplemental Material S6). pathways was correlated with decreased cell viability. In contrast, non-optimal combined targeted inhibition led to inadequate inhibition of the signaling networks and increased cell viability.
Discussion
Integrating mass-action modeling with optimization schemes is a quantitative approach to train ODE models using experimental data and identify optimal drug combinations that can inhibit signaling networks. PSO converged to more optimal solutions than did other optimization algorithms, including simulated annealing and genetic algorithms. Supplemental Table III summarizes the performance of the three algorithms in training the reduced mass-action model In conclusion, we propose a computational procedure that can be used to rapidly generate experimentally testable intervention strategies that may lead to an optimal use of available drugs and the discovery of novel signaling targets. The procedure is currently being used to identify and validate drug combinations that can inhibit aberrant networks in a panel of human cancer cell lines. Cells were left untreated as a control and incubated with LY294002 at its EC 25 (3.8 μM) or rapamycin at its EC 25 (0.1 nM) in combination with U0126 at a concentration of 0.5 to 50 μM.
(B) Cells were left untreated as a control and incubated only with rapamycin at concentrations of 0.1 to 100 nM or with a combination of U0126 at its EC 25 (3.5 μM) and rapamycin at a concentration of 0.5 to 50 μM. Absorbance was normalized with respect to the value detected for
